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Abstract 
Background 
The lipid-lowering effect of fenofibrate is accompanied by a rise in plasma 
homocysteine, a potential risk factor for venous thromboembolism (VTE). This study 
investigated the relationship between homocysteine and the risk of VTE in patients 
treated with fenofibrate. 
Methods and results 
The relationship between homocysteine and deep-vein thrombosis or pulmonary 
embolism was investigated in 9522 participants of the 5-year Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) trial. All subjects received fenofibrate 
during a 6-week active run-in phase before randomization. A Cox proportional-
hazards model was used to assess the effect of homocysteine on risk of venous 
thromboembolic events. 
During active-drug run-in, homocysteine rose on average by 6.5 μmol/L, 
accompanied by a substantial rise in plasma creatinine (+12%). Fenofibrate-induced 
changes in homocysteine and creatinine were fully reversible in the placebo group but 
persisted in the treatment group until reversing at the end of therapy. During follow-
up, 1.8% had at least one episode of deep-vein thrombosis or pulmonary embolism: 
103 on fenofibrate and 68 on placebo (log-rank P=0.006). 
In multivariate analysis, every 5 µmol/L higher baseline homocysteine was associated 
with 19% higher risk of VTE. Fenofibrate treatment was associated with 52% higher 
risk, but the change in homocysteine with fenofibrate was not significantly associated 
with VTE after adjustment for baseline homocysteine.  
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Conclusions 
Hyperhomocysteinemia is prospectively associated with VTE. Fenofibrate may 
predispose individuals with high pretreatment homocysteine towards VTE. The 
fenofibrate-induced increase in homocysteine did not, however, explain the risk 
associated with fenofibrate therapy. 
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Introduction 
Lipid-lowering drug therapy is one of the mainstays of primary and secondary 
prevention of cardiovascular disease 
1-3
. Although statins are the most commonly 
prescribed lipid-lowering agents, they are not the most effective agents for lowering 
triglycerides 
3
. Fibrates, such as fenofibrate, are known to lower triglycerides and, to a 
lesser extent, cholesterol 
4
. Fibrate therapy is of particular relevance in diabetes, 
where triglycerides are often elevated 
5-6
. In the large-scale Fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) trial, long-term fenofibrate treatment 
reduced triglycerides by 27%, total cholesterol by 11%, and LDL cholesterol by 11% 
in patients with type 2 diabetes.
7
 Although fenofibrate did not significantly reduce the 
risk of the primary outcome of coronary events, it did significantly reduce 
cardiovascular events. Furthermore, fenofibrate caused a marked reduction in 
microvascular events including retinopathy, nephropathy and neuropathy. The 
beneficial effects of fenofibrate were evident, despite an associated increase in the 
serum level of homocysteine, which is an established risk factor for CVD 
8
. The 
homocysteine-increasing effect of fenofibrate also raises the question whether 
fenofibrate treatment increases the likelihood of VTE events, because there is some 
evidence that homocysteine increases venous thrombembolism.
9-11
 
Case–control studies from the 1990s reported a high prevalence of mild to moderate 
hyperhomocysteinemia in VTE patients.
9 12-15
 However, the impact of these studies is 
limited by their retrospective nature and the small number of cases. Prospective 
studies have been rare, with a total of 476 cases and 1517 controls in 3 studies.
10
 
Although they generally confirmed hyperhomocysteinemia as a risk factor, the 
associations were statistically weak, creating uncertainty about the causality of 
hyperhomocysteinemia for VTE. The common C677T polymorphism of the 
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methylenetetrahydrofolate reductase (MTHFR) gene also contributes to elevated 
homocysteine concentrations, especially when present in the homozygous form, 
Studies investigating the potential relationship between this polymorphism and 
venous thromboembolism have been inconsistent. A meta-analysis including 
31studies showed a weak association between the MTHFR C677T gene 
polymorphism and an increased risk of venous thromboembolism 
16
. The authors 
speculated that the relationship between hyperhomocysteinemia and venous 
thromboembolism is unlikely to be mediated by this gene defect to a substantial 
degree,  
The limited number of prospective studies and their inconclusive outcomes highlight 
the need for additional prospective data investigating the relationship between serum 
homocysteine and venous thromboembolism. 
Our study investigates the relation between homocysteine and venous thrombolism in 
the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, in which 
patients with type 2 diabetes mellitus were treated with placebo or fenofibrate for an 
average of 5 years. Since fenofibrate is known to increase homocysteine,
8
 we also 
investigated whether fenofibrate-induced changes in homocysteine modify the risk of 
future thrombotic events. 
Material and Methods 
Study design 
The FIELD trial was a multinational, double-blind, placebo-controlled trial in 63 
centers in Australia, New Zealand, and Finland. The study population consisted of 
9795 participants aged 50–75 years who had type 2 diabetes mellitus diagnosed 
according to WHO criteria and who were not taking lipid-modifying therapy at study 
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entry. A detailed description of the design of the study has been published.
17
 Between 
February 1998 and November 2000, patients were randomly allocated to once-daily 
micronised fenofibrate (Laboratoires Fournier, Dijon, France), 200 mg, or placebo. 
Patients were recruited from hospital clinics and community sources. Exclusion 
criteria included renal impairment (blood creatinine >130 μmol/L), known chronic 
liver disease or symptomatic gallbladder disease, and a cardiovascular event within 
the 3 months before recruitment. 
Before randomization all participants entered a standardized run-in phase consisting 
of a 4-week diet-only period, a 6-week single-blind placebo period, and then a 6-week 
single-blind active run-in period on the study treatment (Figure 1). This allows 
determination of the correlation between any long-term clinical effects of treatment 
and short-term alterations associated with the drug, including changes in circulating 
homocysteine levels. Homocysteine results and complete medical records were 
available from 9522 participants at baseline and from 8182 at the end of the active 
run-in phase. 
All patients gave written informed consent. The study protocol was approved by local 
and national ethics committees and was undertaken in accordance with the 
Declaration of Helsinki and Good Clinical Practice guidelines. 
Blood sampling and measurement of homocysteine 
Plasma homocysteine was measured before the 6-week active-treatment run-in (at 
baseline) and at the end (at randomization). Fasting blood samples were collected into 
EDTA tubes. Immediately after collection, samples were separated and frozen on site. 
Frozen samples were transported to one of two central laboratories in Adelaide 
(Australia) and Helsinki (Finland) where they were aliquoted and stored at -80°C until 
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analysis. In the Australian laboratory, plasma homocysteine was assayed by high-
performance liquid chromatography (HPLC) after reduction and derivatization with a 
fluorophore. In Finland a commercial immunoassay was used. These methods are 
known to produce comparable results and were confirmed by the exchange of samples 
between the two laboratories. In both laboratories assay performance was monitored 
over time by internal quality-control procedures and participation in local external 
quality-assurance programs. 
Statistical analysis 
The main outcome studied was the time from randomization to a deep-vein 
thrombosis or pulmonary embolism event. Circulating biomarkers were expressed as 
mean and standard deviation, or median with interquartile range if data were not 
normally distributed. Calculations of relative change were based on log-transformed 
data using the ratio of geometric means.  
Cumulative hazard curves of events according to treatment group were plotted, and 
the log-rank test was used to ascertain the effect of fenofibrate treatment on the first 
venous thromboembolism event. A Cox proportional-hazards model was used to 
assess the effect of homocysteine on risk of venous thromboembolism events. Hazard 
ratios (HRs) and 95% confidence intervals are presented. The proportional-hazards 
assumption was assessed using the Harrell–Lee test18. Selection of predictor variables 
was performed using the backward elimination method. For the purposes of analysis, 
change in homocysteine was defined as the difference between baseline and end-of-
run-in homocysteine levels for each subject in the fenofibrate-randomized group, and 
zero change was attributed to all subjects in the placebo group (based on the lack of 
change in average levels in placebo-treated subjects at 1 year). 
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Since previous studies have speculated about the existence of a homocysteine 
threshold level above which venous thromboembolism risk starts to rise,
9 19-20
 we 
investigated whether there was evidence for such a threshold in the FIELD cohort. 
The relationship between quintiles of homocysteine and risk was assessed in an 
intention-to-treat analysis using an adjusted Cox model. Fractional polynomials, a 
flexible tool for modelling the relationship between the continuous variable, plasma 
homocysteine, and venous thromboembolism, were fitted.
21
 We considered models of 
up to 2 degrees.  
Analyses were performed using SAS version 9.2, and a two-tailed P<0.05 was 
considered significant. 
Results 
Baseline characteristics and effects of fenofibrate on circulating biomarkers 
Participants in the placebo and fenofibrate groups were well matched for baseline 
characteristics, such as age, body mass index, smoking habits, blood pressure and 
duration of diabetes (Table 1). Both groups had a similar history of cardiovascular 
events. The use of glucose-lowering and cardiovascular medication was as expected 
for a cohort of people with diabetes and did not differ between the two groups. 
Baseline homocysteine levels were similar in the placebo group (table 2) and the 
fenofibrate group. Similarly, other biochemical serum or plasma markers including 
creatinine, fibrinogen and lipoprotein (Lp) (a) also showed comparable baseline levels. 
While placebo treatment had no effect on any relevant biomarker over the short-to-
medium term (1 year), fenofibrate induced significant changes in homocysteine and 
creatinine. During the active run-in phase (before randomization; all participants were 
treated with fenofibrate for 6 weeks), plasma homocysteine rose on average by 6.5 
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μmol/L in both groups. The increase in homocysteine was accompanied by a 
substantial rise in plasma creatinine by 10.0 μmol/L (+12%). A Spearman’s 
correlation analysis showed a significant correlation between the change in 
homocysteine and the change in creatinine with a correlation coefficient of r=0.38, P 
<0.001. 
Repeat measurements after one and five years of treatment showed that the 
fenofibrate-induced changes in homocysteine and creatinine were fully reversible in 
those randomized to placebo after active run-in, but persisted in the treatment group 
long-term. However, after randomization to long-term fenofibrate, homocysteine 
stabilized at somewhat lower levels when compared with the initial increase at the end 
of the 6-week run-in phase. In contrast, creatinine levels remained elevated during the 
entire follow up period  
Description of events 
During the follow-up period, 171 patients (1.8% of the entire cohort) had a least one 
deep-vein thrombosis or pulmonary embolism event (221 events). While most of 
these patients (76.6 %) had only one event, 23.4 % sustained two or more. In the 
fenofibrate group 103 patients had an event, compared with 68 patients in the placebo 
group. (Figure 2; log-rank P=0.006). Overall, deep-vein thrombosis was more 
frequent than pulmonary embolism. 110 and 85 patients had at least one deep vein 
thrombosis and pulmonary embolism event, respectively. The HRs comparing the 
incidence of thrombosis events between fenofibrate-and placebo-treated participants 
remained relatively constant throughout the trial, with no statistical heterogeneity 
observed in hazard ratios across arbitrary time periods (0–2 years, 2–4 years, >4 
years). 
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Relationship between homocysteine and the risk of thrombosis events 
Before exploring the relationship between homocysteine and thrombosis risk, 
potential confounders were identified using univariate and multivariate analyses. 
These analyses identified the following parameters as significant predictors of 
thrombotic risk: age, BMI, ethnicity, history of hypertension, history of CVD, 
neuropathy and the albumin/creatinine ratio.  Those remaining significant in 
multivariate analysis were age, ethnicity, history of CVD and BMI. Adjusting for all 
these potential confounders revealed baseline homocysteine and the use of fenofibrate 
as significant independent predictors of thrombosis risk (Table 3). Each 5 µmol/L 
higher plasma homocysteine at baseline was associated with 19% higher risk. 
Fenofibrate treatment was associated with a 52% higher risk of thrombosis.  
Fenofibrate appeared more likely to increase thrombotic risk in those with highest 
baseline homocysteine levels (interaction p=0.04). The change in homocysteine with 
fenofibrate was not significantly associated with thromboembolism after adjustment 
for baseline homocysteine level (Table 4). 
Is there a homocysteine threshold level above which venous thromboembolism risk 
increases? 
The HRs for venous thromboembolism by quintile of plasma homocysteine level 
showed no evidence of a threshold effect. In models of the relationship using plasma 
homocysteine as a continuous variable, none of the models fitted significantly better 
than the linear model, failing to support the existence of a threshold effect. 
Discussion 
This study provides evidence that naturally occurring levels of plasma homocysteine 
are associated with risk of future venous thromboembolism events. A 5 μmol/L 
difference in plasma homocysteine was associated with a 19% difference in the risk of 
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thrombotic events. This observation is in keeping with previous case–control studies 
reporting a high prevalence of hyperhomocysteinemia in venous thromboembolism 
patients.
9 12-15
 Prospective studies are rare, and together comprise a total of only 476 
venous thromboembolism cases and 1517 controls.
10
 Their results were variable 
22-23
. 
For example, Ridker et al. did not find a higher risk of venous thromboembolism in 
people with plasma homocysteine levels ≥17.25 μmol/L compared to those with lower 
levels.
22
 Similarly, Tsai et al. found a nonsignificantly higher thromboembolism risk 
in the highest quintile of serum homocysteine (adjusted odds ratio 1.55; 95% CI, 
0.93–2.58).23 In the present study baseline homocysteine was a significant predictor of 
thrombotic events in the entire cohort but not in the placebo group suggesting that 
overall this relationship is not very strong.  A meta-analysis, pooling the data from all 
available prospective studies showed a 27% increase in thrombosis risk (odds ratio 
1.27; 95% CI, 1.01–1.59) for every 5 μmol/L higher circulating homocysteine,10 
which is comparable to our result. 
The mechanisms underlying the association between homocysteine and venous 
thromboembolism risk are complex and insufficiently understood. Homocysteine 
causes oxidative stress and endothelial damage. Furthermore, it activates platelets, 
promotes local thrombin formation and impairs fibrinolysis 
24-25
.  The induction of 
endothelial tissue factor expression and the inhibition of plasminogen activation by 
tissue plasminogen activator appear to be of pivotal importance 
24 26-27
. For example, 
homocysteine increases the expression of plasminogen activator inhibitor-1 and 
thrombin-activatable fibrinolysis inhibitor  
24 27
. Adverse effects on angiogenesis 
resulting in angiostasis have also been described 
24 26
. It has been suggested that 
hyperhomocysteinemia potentiates the thrombotic risk in carriers of inherited 
thrombophilic factors, such as Factor V Leiden or the prothrombin G20210A 
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mutation 
28
. However, existing studies investigating such interactions are 
contradictory. When compared to normal individuals some studies found a 10- to 50-
fold higher venous thromboembolism risk in hyperhomocysteinaemic carriers of a 
prothrombotic mutation, suggesting a synergistic effect. Other studies were not able to 
confirm this observation. In fact, the co-existence of the C677T MTHFR homozygous 
genotype does not increase the thrombotic risk associated with Factor V Leiden or the 
prothrombin G20210A mutation. As yet, in the FIELD cohort there is no information 
available about the frequency and distribution of these hereditary prothrombotic 
conditions.  
In our study plasma homocysteine promptly rose during fenofibrate treatment. The 
concomitant elevation of plasma creatinine suggests a possible alteration in renal 
metabolism. Previous studies have shown that homocysteine is consistently elevated 
in patients with renal impairment and glomerular filtration rate (GFR) less than 60 
ml/min.
29-31
 Although creatinine increased during fenofibrate therapy in FIELD, the 
albumin/creatinine ratio did not rise suggesting that the excretory renal function was 
not impaired. In addition, the correlation between the change in homocysteine and the 
change in creatinine was relatively weak (R=0.38) suggesting that an altered renal 
homocysteine handling explains only a minor fraction of this effect. When a subset of 
patients was retested after discontinuation of fenofibrate at the end of the study, 
homocysteine levels returned to baseline whilst creatinine levels even fell slightly 
below baseline levels, implying significant reno-protective effects 
32
. Therefore, we 
speculate that the elevation of homocysteine, and possibly creatinine, is due to 
increased synthesis via PPAR alpha activation, as suggested by Luc et al.
33
 
Despite the beneficial effects of fenofibrate on various homoeostatic indices 
34
 and 
inflammatory markers 
35
 the present results suggest fenofibrate use as an independent 
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risk factor for venous thromboembolism (52% risk increase). Although fenofibrate 
also induces a substantial rise in plasma homocysteine levels, the lack of an 
interaction between fenofibrate use and the extent of increase in homocysteine levels 
does not support this being the sole mechanism of the greater risk associated with its 
use. In a previous study Lacut et al. also observed an increased risk of venous 
thromboembolism events in fenofibrate users which was independent of plasma 
homocysteine (OR1.88; 95% CI 1.29 – 2.74) 36. An altered lipid handling may at least 
partly be responsible for this observation. Fenofibrate for example induces the 
expression of uncoupling proteins (UCP), such as UCP 2 and 3, in liver and skeletal 
muscle 
37
. Furthermore, it affects elongase and desaturase, which are important in 
fatty acid metabolism 
38-39
. This may lead to an altered lipid-profile favouring the 
formation of clots 
40
. In contrast to the present findings, other studies, such as the 
recently published ACCORD-Lipid trial, have reported fenofibrate to be safe and did 
not observe increased rates of venous thromboembolism 
41-42
. In the context of a 
relatively weak interaction between baseline homocysteine and fenofibrate this raises 
the possibility that the increased risk associated with fenofibrate in FIELD may be a 
chance false-positive finding from among the several hundred types of safety 
outcomes collected in the FIELD study. Another possibility is that the result is 
confounded by the greater number of patients in the placebo group commencing statin 
use during the study. Statin therapy has been shown to have a modest protective effect 
against venous thromboembolism events,
43
 but a multivariate model adjusting for 
differences in statin use confirmed baseline homocysteine and fenofibrate as 
independent predictors of future venous thromboembolism. ## The results may reflect 
the variable interaction of several factors over the duration of the study. In the early 
phase, the interaction between baseline homocysteine and fenofibrate induced 
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increase in homocysteine may have predominated, whilst in the later phase, when the 
fenofibrate induced increase in homocysteine had abated, the higher rate of statin use 
may have provided relative protection towards the placebo group. The baseline levels 
of other potential thrombophilic risk factors, such as fibrinogen and Lp(a),
25-2829-32
 did 
not show significant associations with future thrombotic events. This emphasizes the 
role of baseline homocysteine and fenofibrate treatment as independent risk factors 
for venous thrombemolism. 
Den Heijer et al. suggested that venous thromboembolism risk starts to rise if natural 
homocysteine levels exceed a threshold of about 17 µmol/L.
9
 Despite higher on-study 
plasma homocysteine levels (approximately 4 µmol/L) and significantly more venous 
thromboembolism events events (+52%)  in the fenofibrate group when compared to 
the placebo group, all our analyses failed to confirm the existence of such a threshold. 
The FIELD cohort had relatively low average plasma homocysteine, and only a few 
participants had elevated plasma homocysteine levels. This may have prevented the 
detection of a homocysteine threshold above which venous thromboembolism risk 
starts to rise.  
In conclusion, data from the FIELD trial confirm previous findings that suggest that 
natural homocysteine levels are an independent risk factor for venous 
thromboembolism events. Unlike the ACCORD Lipid study, in which all participants 
received statin therapy, the use of fenofibrate in FIELD increased the risk for 
thrombotic events, especially in patients with a high pre-treatment plasma 
homocysteine. Although fenofibrate increased homocysteine levels in FIELD, there 
was no interaction between the extent of homocysteine elevation, fenofibrate use and 
venous thromboembolism events risk, It remains to be determined whether or not the 
use of homocysteine-lowering treatments, such as folate and vitamin B12 
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supplementation,
44
 might ameliorate any true fenofibrate-related risk of venous 
thromboembolism events. 
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Table 1: Baseline characteristics of the study population  
Characteristics* 
Placebo 
(n=4767) 
Fenofibrate 
(n=4755) 
Anthropometric data 
  
Male 2972 (62.3%) 2972 (62.5%) 
Age at visit 1 (years, mean[SD]) 62.2 (6.9) 62.2 (6.9) 
Diabetes duration (years, median[IQR]) 5 (2–10) 5 (2–10) 
Body-mass index(kg/m
2
, median[IQR]) 29.8 (26.8–33.4) 29.8 (26.8–33.7) 
Blood pressure: systolic (mmHg, mean[SD]) 140.4 (15.3) 140.4 (15.4) 
Blood pressure: diastolic (mmHg, mean[SD]) 81.9 (8.5) 82.0 (8.5) 
Current smoker 449 (9.4%) 441 (9.3%) 
Exsmoker 2432 (51.0%) 2392 (50.3%) 
Clinical history   
Prior cardiovascular disease 1031 (21.6%) 1026 (21.6%) 
Prior myocardial infarction 247 (5.2%) 217 (4.6%) 
Prior stroke 175 (3.7%) 159 (3.3%) 
Prior angina 566 (11.9%) 570 (12.0%) 
Prior coronary revascularization 162 (3.4%) 184 (3.9%) 
History of hypertension 2678 (56.2%) 2700 (56.8%) 
History of diabetic retinopathy 396 (8.3%) 388 (8.2%) 
History of diabetic neuropathy 661 (13.9%) 672 (14.1%) 
History of diabetic nephropathy 130 (2.7%) 139 (2.9%) 
Baseline cardiovascular medication   
Warfarin 114 (2.4%) 118 (2.5%) 
Antiplatelet alone 1380 (28.9%) 1367 (28.7%) 
Neither 3273 (68.7%) 3270 (68.8%) 
Baseline blood-glucose-lowering medication   
Diet alone 1283 (26.9%) 1266 (26.6%) 
Insulin 645 (13.5%) 646 (13.6%) 
Metformin, sulfonylurea, or other oral agent 2839 (59.6%) 2843 (59.8%) 
* Normally distributed variables are shown as mean (SD), non-normally distributed as median (25th to 
75th interquartile range) 
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Table 2: Serial measurements of relevant biochemical markers. Results are shown as mean 
(SD) if distributed normally or median (25th to 75th quartile) 
Marker and time points 
Placebo 
(n=4767) 
Fenofibrate 
(n=4755) 
Homocysteine (umol/L)   
Baseline  9.6 (8.0–11.4) 9.5 (7.9–11.6) 
End of run-in 15.9 (13.5–19.1) 16.0 (13.5–19.2) 
1 year 9.4 (8.0–11.4) 13.4 (11.0–16.4) † 
Study end 11.1 (9.3–13.6) 15.1 (12.3–18.7) † 
Creatinine (umol/L)   
Baseline  77.3 (15.7) 77.7 (15.9) 
End of run-in 87.2 (20.3) 87.8 (20.6) 
1 year 76.5 (19.4) 88.7 (22.6) † 
Study end 85.3 (26.3) 96.4 (34.0) † 
Albumin/creatinine (mg/mmol)   
Baseline 1.10 (0.60–2.90) 1.15 (0.60–3.00) 
Study end 1.00 (0.40–3.10) 0.80 (0.40–2.40) † 
Fibrinogen (g/L)   
Baseline 3.58 (0.73) 3.60 (0.75) 
End of run-in 3.11 (0.74) 3.12 (0.77) 
1 year  3.42 (0.90) 2.94 (0.79) † 
Study end 4.05 (0.97) 3.45 (0.89) † 
Lipoprotein(a) (mg/L)   
Baseline 91 (35–263) 89 (36–258) 
End of run-in 96 (39–265) 96 (39–260) 
Study end 100 (48–256) 86 (40–217)* 
Apolipoprotein A2 (g/L)   
Baseline 0.35 (0.07) 0.35 (0.07) 
End of run-in 0.45 (0.10) 0.45 (0.10) 
Study end 0.35 (0.08) 0.45 (0.11) † 
* P<0.05, † P<0.001 for the comparison between treatment groups. 
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Table 3: Multivariate analysis of predictors of venous thrombosis events 
Predictor Hazard ratio (95% CI) P 
Caucasian 3.09 (1.15–8.35) 0.03 
Age (years) 1.03 (1.01–1.06) 0.008 
Prior cardiovascular disease 1.45 (1.04–2.02) 0.03 
Body-mass index (kg/m
2
) 1.07 (1.05–1.10) <0.001 
Homocysteine at baseline (per 5 µmol/L) 1.19 (1.06–1.32) 0.002 
Fenofibrate 1.52 (1.12–2.06) 0.008 
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Table 4: Effect of change in homocysteine between baseline and end of run-in risk of 
venous thrombosis 
Model and variables Hazard ratio (95% CI) P 
Difference in homocysteine between baseline 
and end of run-in (per 5 µmol/L) 
1.05 (0.83–1.33) 0.71 
Fenofibrate 1.40 (0.87–2.26) 0.17 
Homocysteine at baseline (per 5 µmol/L) 1.20 (1.04–1.40) 0.01 
* Model was adjusted for age, ethnicity (Caucasian vs. other), body-mass index at baseline and prior 
cardiovascular disease. 
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Figure legends 
Figure 1 
Flow chart illustrating the design of the FIELD study. 
Figure 2 
Hazard plot showing the cumulative risk of the time to first deep-vein thrombosis or 
pulmonary embolism, by treatment group. 
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